Our previous study has identified the role of small molecule inhibitor bufalin in inhibiting the progression of CRC by suppressing SRC‐1 protein, while its role in inhibiting CRC immune escape is unclear. This evidence concerns the gene NCOA1 and colorectal carcinoma.